ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

In Memoriam: Aline Wilmot Skaggs (1926 – 2015)

January 26, 2015 – 1:00 am | Edit Post

Aline Wilmot Skaggs was a generous benefactor to TSRI and other causes through the family foundation, The ALSAM Foundation.

In Memoriam: Aline Wilmot Skaggs (1926 – 2015)

January 26, 2015 – 1:00 am | Edit Post

Aline Wilmot Skaggs was a generous benefactor to TSRI and other causes through the family foundation, The ALSAM Foundation.

New Powered Vascular Stapler From Ethicon, Inc. Offers Greater Precision During Thoracic Surgery

January 25, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 26, 2015 /PRNewswire/ –Ethicon* has developed a new powered vascular stapler designed to provide greater precision and stability than currently available staplers for critical vessel transections. The new ECHELON FLEXTMPowered Vascular…

Myriad Genetics, Inc. And Pathway Genomics Corporation Agree To Settle BRCA Patent Infringement Case

January 25, 2015 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Pathway Genomics Corporation (Pathway) today announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014. Under the agreement, Myriad Genetics, Inc., the University of Ut…

Mast Therapeutics Announces Management Change

January 25, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 24, 2015 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced a management change in connection with a restructuring of management to…

Myriad Genetics, Inc. And Pathway Diagnostics Agree To Settle BRCA Patent Infringement Case

January 25, 2015 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Pathway Genomics Corporation (Pathway) today announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014. Under the agreement, Myriad Genetics, Inc., the University of Ut…

ClearFlow Exhibits PleuraFlow System At <b>Society Of Thoracic Surgeons Annual Meeting</b>

January 25, 2015 – 5:00 pm | Edit Post

ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow Active Clearance Technology System at the Society of Thoracic Surgeons (STS) 51st Annual Meeting in San Diego. PleuraFlow will continue to …

Epic Sciences To Present At On The Use Of Circulating Tumor Cells As Cancer Biomarkers

January 25, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 26, 2015 /PRNewswire/ –Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president and CEO, is scheduled…

Genedata Announces Strong Adoption Of High Content Screening In Pharma R&D Running <b>Genedata</b> Screener

January 25, 2015 – 5:00 pm | Edit Post

At 12th Annual HCA, Genedata presents latest developments for HCS and phenotypic screening San Diego, Calif. – January 26, 2015 — Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announce…

Mast Therapeutics Announces Management Change

January 24, 2015 – 5:30 pm | Edit Post
Mast Therapeutics Announces Management Change

SAN DIEGO, Jan. 24, 2015 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced a management change in connection with a restructuring of management to best support the Company in its current stage of development.  The Company’s President and Chief Operating Officer, Patrick L. Keran, will step down from that role and be leaving the Company effective February 28, 2015.  

“We would like to thank Pat for his tireless work and dedication over the years,” stated Jack Lief, Chair of the Board of Directors. “He has been an instrumental member of the team and contributed significantly to the Company’s operations.”   

“Pat’s contributions have been vital as we moved through some fundamental changes in recent years, which included multiple strategic acquisitions, and advanced our development programs to where they are today. The experience he’s gained will no doubt serve him well in the next stage of his career and I’m sure he’ll be successful in his future endeavors,” stated Brian M. Culley, Chief Executive Officer.  

About Mast Therapeutics  
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes. 

The Company is enrolling subjects in EPIC, a pivotal Phase 3 study of vepoloxamer in sickle cell disease, and in a Phase 2 study to evaluate whether vepoloxamer improves the effectiveness of recombinant tissue plasminogen activator therapy in patients with acute limb ischemia.  The Company also is planning to initiate a Phase 2 study of vepoloxamer in patients with acute decompensated heart failure in the first half of 2015. More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements  
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to anticipated milestones for the Company’s development programs. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a “clinical hold,” and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the uncertainty of outcomes in ongoing and future studies of the Company’s product candidates and the risk that its product candidates, including vepoloxamer, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of a planned clinical study of a product candidate; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the Company’s reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, manufacturing, and regulatory activities for its product candidates, and that such third parties may fail to perform as expected; the Company’s ability to obtain additional funding as needed on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success with its products and may never generate revenue sufficient to achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights relating to the MAST platform and vepoloxamer or AIR001 and prevent competitors from duplicating or developing equivalent versions of its product candidates; and other risks and uncertainties more fully described in the Company’s press releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Photo – http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 

 

SOURCE Mast Therapeutics